Staff

Professor Brian Lipworth

Papers on original research

A1 LIPWORTH BJ, MCDEVITT DG, STRUTHERS AD. Prior treatment with diuretic augments the hypokalaemic and electrocardiographic effects of inhaled albuterol. American Journal of Medicine 1989; 86: 653-657.

A2 LIPWORTH BJ, STRUTHERS AD, MCDEVITT DG. Tachyphylaxis to systemic but not airways response during prolonged therapy with high dose inhaled salbutamol in asthmatics. American Review of Respiratory Disease 1989; 140: 586-592

A3 LIPWORTH BJ, CLARK RA, DHILLON DP, MCDEVITT DG. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on beta-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. American Review of Respiratory Disease 1990; 142: 338-342.

A4 LIPWORTH BJ, MCDEVITT DG, STRUTHER AD. Hypokalaemic and ECG sequelae of combined -agonist/diuretic therapy: protection by conventional doses of spironolactone but not triamterene. Chest 1990; 98: 811-815.

A5 LIPWORTH BJ, MCDEVITT DG, STRUTHERS AD. Electrocardiographic changes induced by inhaled salbutamol after treatment with bendofluazide: effects of replacement therapy with potassium, magnesium and triamterene. Clinical Science 1990; 78: 255-259.

A6 LIPWORTH BJ, CLARK RA, DHILLON DP, BROWN RA, MCDEVITT DG. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. British Journal of Clinical Pharmacology 1988; 26: 527-533.

A7 LIPWORTH BJ, CLARK RA, DHILLON DP, MCDEVITT DG. Subsensitivity -adrenoceptor responses in asthmatic patients taking regular low dose inhaled salbutamol. Journal of Clinical Pharmacology 1990; 38: 203-205.

A8 LIPWORTH BJ, CLARK RA, FRASER CG, MCDEVITT DG. The biochemical effects of high dose inhaled salbutamol in patients with asthma. European Journal of Clinical Pharmacology 1989; 36: 357-360.

A9 LIPWORTH BJ, MCDEVITT DG, STRUTHERS AD. Systemic -adrenoceptor responses to salbutamol given by metered dose inhaler alone and with pear-shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. British Journal of Clinical Pharmacology 1989; 27: 837-842.

A10 LIPWORTH BJ, CLARK RA, DHILLON DP, MORELAND TA, STRUTHERS AD, CLARK GA, MCDEVITT DG. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. European Journal of Clinical Pharmacology 1989; 37: 567-571.

A11 LIPWORTH BJ, CLARK RA, CHARTER MK, PALMER JBD, MCDEVITT DG. Single dose and steady state pharmacokinetics of 4mg and 8mg oral controlled release salbutamol in patients with asthma. European Journal of Clinical Pharmacology 1989; 37: 49-52.

A12 LIPWORTH BJ, CLARK RA, DHILLON DP, PALMER JBD, MCDEVITT DG. Comparison of the efficacy and systemic effect of 4mg and 8mg salbutamol controlled release in patients with asthma. European Journal of Clinical Pharmacology 1990; 39: 281-285.

A13 LIPWORTH BJ & MCDEVITT DG. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. European Journal of Clinical Pharmacology 1989; 36: 239-245.

A14 LIPWORTH BJ, TREGASKIS BF, MCDEVITT DG. Beta-adrenoceptor responses to inhaled salbutamol in the elderly. British Journal of Clinical Pharmacology 1989; 28: 725-729.

A15 LIPWORTHBJ, CLARK RA, MCDEVITT DG. Measurement of normal human airway response to -adrenoceptor stimulation using a forced oscillation technique. Journal of Clinical Pharmacy and Therapeutics 1991; 16: 187-191.

A16 LIPWORTH BJ, BROWN RA, MCDEVITT DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of 2-adrenoceptor blockade. British Journal of Clinical Pharmacology 1989; 28: 95-102.

A17 LIPWORTH BJ, MCFARLANE LC, COUTIE WJ, MCDEVITT DG. Evaluation of metabolic responses to inhaled salbutamol in the measurement of 2-adrenoceptor blockade. European Journal of Clinical Pharmacology 1989; 37: 297-300.

A18 IRVINE NA, LIPWORTH BJ, MCDEVITT DG. A dose-ranging study to evaluate 2-adrenoceptor selectivity of single doses of betaxolol. British Journal of Clinical Pharmacology 1990; 30: 119-126.

A19 LIPWORTH BJ, IRVINE NS, MCDEVITT DG. The effects of time and dose on the relative 1 and 2-adrenoceptor antagonism of betaxolol and atenolol. British Journal of Clinical Pharmacology 1991; 31: 154-159.

A20 LIPWORTH BJ, IRVINE NA, MCDEVITT DG. A dose-ranging study to evaluate the 1-adrenoceptor selectivity of bisoprolol. European Journal of Clinical Pharmacology 1991; 40: 135-139.

A21 LIPWORTH BJ, TREGASKIS BF, MCDEVITT DG. Comparison of hypokalaemic electrocardiographic and haemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. European Journal of Clinical Pharmacology 1991; 40: 225-260.

A22 LIPWORTH BJ, IRVINE NA, MCDEVITT DG. The effects of chronic dosing on the 1- and 2-adrenoceptor antagonism of betaxolol and atenolol. European Journal of Clinical Pharmacology 1991; 40: 467-471.

A23 WHEELDON NM, NEWNHAM DM, FRASER CG, MCDEVITT DG, LIPWORTH BJ. The effect of pindolol on creatine kinase is not due to 2-adrenoceptor partial agonist activity. British Journal of Clinical Pharmacology 1991; 31: 723-724.

A24 NEWNHAM DM, MCDEVITT DG, LIPWORTH BJ. The effects of frusemide and triamterene on the hypokalaemic and electrocardiographic response to inhaled terbutaline. British Journal of Clinical Pharmacology 1991; 32: 630-632.

A25 WHEELDON NM, MCDEVITT DG, LIPWORTH BJ. Evaluation of in vivo partial agonist activity: a dose-ranging study with carteolol. British Journal of Clinical Pharmacology 1992; 33: 411-416.

A26 RAHMAN ARA, MCDEVITT DG, STRUTHERS AD, LIPWORTH BJ. The effects of enalapril and spironolactone on terbutaline induced hypokalaemia. Chest 1992; 102: 91-95.

A27 WHEELDON NM, MCDEVITT DG, LIPWORTH BJ. Selectivity of antagonist and partial agonist activity of celiprolol in normal subjects. British Journal of Clinical Pharmacology 1992; 34: 337-343.

A28 LIPWORTH BJ, JACKSON CM, ZIYAIE D, WINTER JH, DHILLON DP, CLARK RA. An audit of acute asthma admissions to a respiratory unit. Health Bulletin 1992; 50: 389-398.

A29 WHEELDON NM, PRINGLE TH, LIPWORTH BJ. Obstructive left ventricular hypertrophy: Reversibility of outflow obstruction by drug therapy. Quarterly Journal of Medicine 1992; 84: 629-636.

A30 LANG CC, COUTIE WJ, STRUTHERS AD, DHILLON DP, WINTER JH, LIPWORTH BJ. Elevated levels of brain natriuretic peptide in acute hypoxzaemic chronic obstructive pulmonary disease. Clinical Science 1992; 83: 529-533.

A31 RAHMAN ARA, MCDEVITT, STRUTHERS AD, LIPWORTH BJ. Sex differences in hypokalaemic and electrocardiographic effects of inhaled terbutaline. Thorax 1992; 47: 1056-1059.

A32 WHEELDON NM, MCDEVITT DG, LIPWORTH BJ. Investigation of putative cardiac 3-adrenoceptors in man. Quarterly Journal of Medicine 1993; 86: 255-261.

A33 NEWNHAM DM, WHEELDON NM, LIPWORTH BJ, MCDEVITT DG. A single dosing comparison of the relative 1/ 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 1993; 48: 656-658.

A34 LIPWORTH BJ, ALLAN J, JACKSON CM, DHILLON DP, WINTER JH, CLARK RA. An audit of hospital discharge letters in patients admitted with acute asthma. Scottish Medical Journal 1993; 38: 116-119.

A35 NEWNHAM DM, DHILLON DP, WINTER JH, JACKSON CM, CLARK RA, LIPWORTH BJ. Bronchodilator reversibility to low and high dose of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993; 48: 1151-1155.

A36 WHEELDON NM, MCDEVITT DG, LIPWORTH BJ. Do 3-adrenoceptors mediate metabolic responses to isoprenaline. Quarterly Journal of Medicine 1993; 86: 595-600.

A37 NEWNHAM DM, MCDEVITT DG, LIPWORTH BJ. Comparison of extrapulmonary 2-responses and pharmacokinetics of salbutamol given by standard metered-dose inhaler and modified actuator device. British Journal of Clinical Pharmacology 1993; 36: 445-450.

A38 NEWNHAM DM, INGRAM CG, MACKIE A, LIPWORTH BJ. Beta-adrenoceptor subtypes mediating the airway response to BRL 35135 in man. British Journal of Clinical Pharmacology 1993; 36: 567-571.

A39 NEWNHAM DM, COUTIE WJ, MCFARLANE LC, LIPWORTH BJ. Comparison of in vitro parameters of lymphocyte 2-adrenoceptor function in normal and asthmatic subjects. European Journal of Clinical Pharmacology 1993; 45: 535-538.

A40 LIPWORTH BJ, DAGG KD. Comparative effects of angiotensin II on Doppler parameters of left and right heart systolic and diastolic blood flow. British Journal of Clinical Pharmacology 1994; 37: 273-278.

A41 WHEELDON NM, MCDEVITT DG, MCFARLANE LC, LIPWORTH BJ. Beta-adrenoceptor subtypes which mediate the metabolic effects of BRL 35135 in man. Clinical Science 1994; 86: 331-337.

A42 WHEELDON NM, MCDEVITT DG, LIPWORTH. Cardiac effects of 3-agonist BRL 35135 in man. British Journal of Clinical Pharmacology 1994; 37: 363-369.

A43 RAMAGE L, LIPWORTH BJ, INGRAM CG, CREE IA, DHILLON DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respiratory Medicine 1994; 88: 363-368.

A44 LIPWORTH BJ, DAGG KD. Vasoconstrictor effects of angiotensin II on the pulmonary vascular bed. Chest 1994; 105: 1360-1364.

A45 NEWNHAM DM, MCDEVITT DG, LIPWORTH BJ. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. American Journal of Medicine 1994; 97: 29-37.

A46 WHEELDON NM, NEWNHAM DM, COUTIE WJ, PETERS JA, MCDEVITT DG, LIPWORTH BJ. Influence of sex-steroid hormones on the regulation of lymphocyte 2-adrenoceptors during the menstrual cycle. British Journal of Clinical Pharmacology 1994; 37: 583-588.

A47 WHEELDON NM, MCDEVITT DG, LIPWORTH BJ. The effects of lower than conventional doses of nadolol on relative 1/ 2-adrenoceptor blockade. British Journal of Clinical Pharmacology 1994; 38: 103-108.

A48 CARGILL RI, COUTIE WJ, LIPWORTH BJ. The effects of angiotensin II on circulating levels of natriuretic peptides in man. British Journal of Clinical Pharmacology 1994; 38: 139-142.

A49 NEWNHAM DM, WHEELDON NM, MCFARLANE LC, CLARK GA, MCDEVITT DG, LIPWORTH BJ. Extrapulmonary 2-responses to intravenous salbutamol during the menstrual cycle. European Journal of Clinical Pharmacology 1994; 46: 511-515.

A50 LANG CC, PRASAD N, MCALPINE HM, MACLEOD C, LIPWORTH BJ, MACDONALD TM, STRUTHERS AD. Increased plasma levels of brain natriuretic peptide in patients with isolated diastolic dysfunction. American Heart Journal 1994; 127: 1635-1636.

A51 NEWNHAM DM, LIPWORTH BJ. Nebuliser performance, pharmacokinetics, bronchodilator and systemic effects of salbutamol given by a novel nebuliser system (Ventstream). Thorax 1994; 49: 762-770.

A52 GROVE A, ALLAM C, MACFARLANE LC, MCPHATE G, JACKSON CM, LIPWORTH BJ. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. British Journal of Clinical Pharmacology 1994; 38: 527-532.

A53 LIPWORTH BJ, NEWNHAM DM, CLARK RA, DHILLON DP, WINTER JH, MCDEVITT DG. Comparison of the relative airway and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50: 54-61.

A54 CARGILL RI, STRUTHERS AD, LIPWORTH BJ. Comparative effects of ANP and BNP on the aldosterone and pressor response to angiotensin II in man. Clinical Science 1995; 88: 81-86.

A55 CARGILL RI, STRUTHERS AD, LIPWORTH BJ. Human C-type natriuretic peptide: effects on the haemodynamic and endocrine responses to angiotensin II. Cardiovascular Research 1995; 29: 108-111.

A56 CARGILL RI, BARR CS, COUTIE WJ, STRUTHERS AD, LIPWORTH BJ. C-type natriuretic peptide levels in cor pulmonale and congestive heart failure. Thorax 1994; 49: 1247-1249.

A57 SMITH RP, LIPWORTH BJ. C-reactive protein in simple community acquired pneumonia. Chest 1995; 107: 1028-1031.

A58 GROVE A, MCFALRANE LC, LIPWORTH BJ. Expression of the 2-adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone. Thorax 1995; 50: 134-138.

A59 CARGILL RI, LIPWORTH BJ. Pulmonary vasorelaxant activity of ANP and BNP in man. Thorax 1995: 50: 183-185.

A60 CARGILL RI, LIPWORTH BJ. Acute effects of hypoxaemia and angiotensin II in the human pulmonary vascular bed. Pulmonary Pharmacology 1994; 7: 305-310.

A61 GROVE A, LIPWORTH BJ, INGRAM CG, CLARK RA, DHILLON DP. A comparison of prednisolone and mianserin on ventilatory, exercise and psychometric parameters in chronic obstructive pulmonary disease. European Journal of Clinical Pharmacology 1995; 48: 13-18.

A62 NEWNHAM DM, GROVE A, MCDEVITT DG, LIPWORTH BJ. Subsensitivity of bronchodilator and systemic 2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995; 50: 497-504.

A63 CARGILL RI, CLARKSON PBM, MACDONALD TM, LIPWORTH BJ. Profound vagal reactions to brain natriuretic peptide. Journal of Molecular Medicine 1995; 73: 149-150.

A64 BOYTER AC, DAVIE PG, HUDSON SA, CLARK RA, LIPWORTH BJ. Evaluation of an antibiotic prescribing protocol for treatment of acute exacerbations of chronic obstructive airways disease in a hospital respiratory unit. Journal of Antimicrobial Chemotherapy 1995; 36: 403-409.

A65 CARGILL RI, MCFARLANE LC, COUTIE W, LIPWORTH BJ. Acute neurohormonal responses to hypoxaemia in man. Eur J Appl Physiol 1996; 72:256-260

A66 CARGILL RI, KIELY DG, LIPWORTH BJ. Left ventricular systolic performance during hypoxaemia. Chest 1995; 108: 899-902.

A67 GROVE A, LIPWORTH BJ. Bronchodilator subsensitivity to inhaled salbutamol after twice daily salmeterol in asthmatic patients. Lancet 1995; 346: 201-206.

A68 LANG CC, MCALPINE HM, KENNEDY N, RAHMAN AA, LIPWORTH BJ,, STRUTHERS AD. Effects of lisinopril on congestive heart failure in normotensive patients with diastolic dysfunction but intact systolic function. European Journal of Clinical Pharmacology 1995; 49: 15-19.

A69 SMITH RP, LIPWORTH BJ, CREE IA, SPIERS EM, WINTER JH. C-reactive protein, a clinical marker in community acquired pneumonia. Chest 1995; 108: 1288-1291.

A70 KIELY DG, CARGILL RI, LIPWORTH BJ. Cardiopulmonary interactions of salbutamol and hypoxaemia in healthy young volunteers. British Journal of Clinical Pharmacology 1995; 40: 313-318.

A71 CARGILL RI, LIPWORTH BJ. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. British Journal of Clinical Pharmacology 1995; 40: 585-590.

A72 CARGILL RI, LIPWORTH BJ. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest 1996; 109: 424-429.

A73 KIELY DG, CARGILL RI, GROVE A, STRUTHERS AD, LIPWORTH BJ. Abnormal myocardial repolarisation in response to hypoxaemia and fenoterol. Thorax 1995; 50: 1061-1066.

A74 GROVE A, LIPWORTH BJ. Evaluation of 2-adrenoceptor agonist/antagonist activity of salmeterol and formoterol. Thorax 1996; 51: 54-58.

A75 KIELY DG, CARGILL RI, LIPWORTH BJ. Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Cardiovascular Research 1995; 30: 875-880.

A76 CARGILL RI, KIELY DG, CLARK RA, LIPWORTH BJ. Hypoxaemia and release of endothelin-I. Thorax 1995; 50: 1308-1310.

A77 CARGILL RI, KIELY DG, LIPWORTH BJ. Adverse effects of hypoxaemia on diastolic filling in humans. Clinical Science 1995; 89: 165-169.

A78 CLARK DJ, GROVE A, CARGILL RI, LIPWORTH BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262-266.

A79 TAN KS, GROVE A, CARGILL RI, MCFARLANE LC, LIPWORTH BJ. Effects of inhaled fluticasone propionate and oral prednisolone on lymphocyte 2-adrenoceptor function in asthmatic patients. Chest 1996; 109: 343-347.

A80 GROVE A, LIPWORTH BJ, REID P, SMITH RP, RAMAGE L, INGRAM CG, JENKIN RJ, WINTER JH, DHILLON DP. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689-693.

A81 CLARK DJ, CLARK G, LIPWORTH BJ. Lung bioavailability of chloroflurocarbon-free aerosol, dry powder and chloroflurocarbon containing formulation of salbutamol. British Journal of Clinical Pharmacology 1996; 41: 247-249.

A82 CLARK DJ, GORDON SMITH J, CLARK G, MCPHATE G, LIPWORTH BJ. Lung bioavailability of generic and innovator salbutamol metered-dose inhalers. Thorax 1996; 51: 325-326.

A83 GROVE A, MCFALRANE LC, JACKSON C, LIPWORTH BJ. Effects of short term exposure to high dose inhaled corticosteroids on novel markers of bone metabolism. European Journal of Clinical Pharmacology 1996; 50: 275-277.

A84 KIELY DG, CARGILL RI, LIPWORTH BJ. Effects of hypercapnia on haemodynamic, inotropic, lusitropic and electrophysiological indices in man. Chest 1996; 109: 1215-1221.

A85 TAN KS, MCFARLANE LC, COUTIE WJ, LIPWORTH BJ. Effects of exogenous female sex-steroid hormones on lymphocyte 2-adrenoceptors in normal females. British Journal of Clinical Pharmacology 1996; 5: 414-416.

A86 GROVE A, LIPWORTH BJ. Effects of prior treatment with salmeterol and formoterol on airway and systemic 2-responses to fenoterol. Thorax 1996; 51: 585-589.

A87 CLARK DJ, LIPWORTH BJ. Effect of multiple actuations, delayed in inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996; 51: 981-984.

A88 KIELY DG, CARGILL RI, LIPWORTH BJ. Angiotensin II receptor blockade and effects on pulmonary haemodynamics and hypoxic pulmonary vasoconstriction in humans. Chest 1996; 110: 698-703.

A89 KIELY DG, CARGILL RI, LIPWORTH BJ. Effects of frusemide and hypoxia on the pulmonary vascular bed in man. British Journal of Clinical Pharmacology 1997; 43: 309-313.

A90 EVANS J, HAYES JL, LIPWORTH BJ, MACDONALD TM. Potentially hazardous co-prescribing of adrenoceptor antagonists and agonists in the community. British Journal of General Practice 1996; 46: 423-425.

A91 CLARK DJ, CLARK RA, LIPWORTH BJ. Adrenal suppression with inhaled budesonide and fluticasone propionate given via large volume spacer to asthmatic children. Thorax 1996; 51: 941-943.

A92 CLARK DJ, TAN KS, LIPWORTH BJ. Evaluation of plasma and urinary salbutamol levels in COPD. European Journal of Clinical Pharmacology 1996; 51: 91-93.

A93 CARGILL RI, LIPWORTH BJ. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Haemodynamic and endocrine effects. Chest 1996; 110: 1220-1225.

A94 KIELY DG, CARGILL RI, STRUTHERS AD, LIPWORTH BJ. Cardiopulmonary effects of endothelin-I in man. Cardiovascular Research 1997; 33: 378-386.

A95 CLARK DJ, LIPWORTH BJ. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 1997; 52: 55-58.

A96 KIELY DG, CARGILL RI, WHEELDON NM, COUTIE WJ, LIPWORTH BJ. Haemodynamic and endocrine effect of type I angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovascular Research 1997; 33: 201-208.

A97 MATHER R, CLARK RA, DHILLON DP, WINTER JH, LIPWORTH BJ. A repeat audit of hospital discharge letters in patients admitted with acute asthma. Scottish Medical Journal 1997; 42: 19-21.

A98 MATHER R, CLARK RA, DHILLON DP, WINTER JH, LIPWORTH BJ. Reaudit of acute asthma admissions using severity marker stamp and determinants of an outcome measure. Scottish Medical Journal 1997; 42: 49-52.

A99 TAN KS, MCFARLANE LC, LIPWORTH BJ. Modulation of airway reactivity and peak flow variability in asthmatic patients receiving the contraceptive pill. American Journal of Respiratory and Critical Care Medicine 1997; 155: 1273-1277.

A100 TAN KS, GROVE A, MCLEAN A, GNOSSPELIUS Y, LIPWORTH BJ. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. American Journal of Respiratory and Critical Care Medicine 1997; 156: 28-35.

A101 CLARK DJ, LIPWORTH BJ. Evaluation of corticotropin releasing factor stimulation and basal markers of HPA-axis suppression in asthmatic patients. Chest 1997; 112: 1248-1252.

A102 TAN KS, MCFARLANE LC, LIPWORTH BJ. Paradoxical down-regulation and desensitization of 2-adrenoceptors by exogenous progesterone in female asthmatics. Chest 1997; 111: 847-851.

A103 TANK KS, MCFARLANE LC, LIPWORTH BJ. Loss of normal cyclical 2-adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatics. Thorax 1997; 52: 608-611.

A104 LIPWORTH BJ, CLARK DJ. Lung bioavailability of salbutamol given by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber). European Respiratory Journal 1997; 10: 1820-1823.

A105 TAN KS, MCFARLANE LC, LIPWORTH BJ. Effects of exogenous female sex steroid hormones on 2-adrenoceptors in healthy males. European Journal of Clinical Pharmacology 1997; 52: 281-283.

A106 TAN KS, MCFARLANE LC, LIPWORTH BJ. Effects of oral and inhaled corticosteroid on lymphocyte 2-adrenoceptor function in asthmatic patients. British Journal of Clinical Pharmacology 1997; 44: 565-568.

A107 LIPWORTH BJ, CLARK DJ, MCFARLANE LC. Adrenocortical activity with repeated twice daily dosing of inhaled fluticasone propionate and budesonide given via large volume spacer to asthmatic school children. Thorax 1997; 52: 686-689.

A108 WILSON AM, CLARK DJ, MCFARLANE LC, LIPWORTH BJ. Adrenal suppression with high doses of inhaled fluticasone propionate and triamcinolone acetonide in healthy volunteers. European Journal of Clinical Pharmacology 1997; 53: 33-37.

A109 WILSON A, MCFARLANE LC, LIPWORTH BJ. Dose response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. American Journal of Respiratory and Critical Care Medicine 1997; 156: 1274-1277.

A110 LIPWORTH BJ, CLARK DJ, KICH, P, ARBEENY C. Pharmacokinetics and extrapulmonary 2-adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax 1997; 52: 849-852.

A111 LIPWORTH BJ, CLARK DJ. Comparative lung delivery of salbutamol given via turbuhaler and diskus dry powder inhaler devices. European Journal of Clinical Pharmacology 1997; 53: 47-49.

A112 LIPWORTH BJ, CLARK DJ. Effects of airway calibre on the lung delivery of nebulised salbutamol. Thorax 1997; 52: 1036-1039.

A113 TAN KS, HALL IP, DEWAR J, DOW E, LIPWORTH BJ. Association between 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmat ics. Lancet 1997; 350: 995-999.

A114 RAMSAYSG, DAGG KD, MCKAY IC, LIPWORTH BJ, MCSHARRY C, THOMSON NC. Investigations on the renin-angiotensin system in acute severe asthma. European Respiratory Journal 1997; 10: 2766-2771.

A115 TAN KS, MCFARLANE LC, LIPWORTH BJ. Concomitant administration of low dose prednisolone protects against in vivo 2-adrenoceptor subsensitivity induced by regular formoterol. Chest 1998; 113: 34-41.

A116 TAN KS, MCFARLANE LC, LIPWORTH BJ. 2-adrenoceptor regulation and function in female asthmatics receiving the oral combined contraceptive pill. Chest 1998; 113: 278-282.

A117 WILSON AM, CLARK DJ, DEVLIN MM, MCFARLANE LC, LIPWORTH BJ. Adrenocortical activity with repeated administration of once daily inhaled fluticasone propionate and budesonide in asthmatic adults. European Journal of Clinical Pharmacology 1998; 53: 317-320.

A118 LIPWORTH BJ, CLARK DJ. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared to an open vent jet nebuliser. British Journal of Clinical Pharmacology 1998; 45: 160-163.

A119 WILSON AM, MCFARLANE LC, LIPWORTH BJ. Effects of low and high doses of inhaled flunisolide and triamcinolone acetonide on basal and dynamic measures of adrenocortical activity in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 1998; 83: 922-925.

A120 AZIZ I, HALL IP, MCFARLANE LC, LIPWORTH BJ. 2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. Journal of Allergy and Clinical Immunology 1998; 101: 337-341.

A121 WILSON AM, MCFARLANE LC, LIPWORTH BJ. Effects of repeated once daily dosing with three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal axis activity. Journal of Allergy and Clinical Immunology 1998; 101: 470-474.

A122 LIPWORTH B, TAN S, DEVLIN M, AIKEN T, BAKER R, HENDRICK D. Effects of treatment with formoterol on bronchoprotection against methacholine. American Journal of Medicine 1998; 104: 431-438.

A123 KIELY DG, LEE AFC, STRUTHERS AD, LIPWORTH BJ. Nitric oxide: an important role in the maintenance of systemic and pulmonary vascular tone in man. British Journal of Clinical Pharmacology 1998; 46: 263-266.

A124 LIPWORTH BJ, CLARK DJ. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. British Journal of Clinical Pharmacology 1998; 46: 45-48.

A125 LIPWORTH BJ, CLARK DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulmonary Pharmacology and Therapeutics 1997; 10: 211-214.

A126 WILSON AM, MCFARLANE LC, LIPWORTH BJ. Systemic bioactivity profiles of oral prednisolone and nebulised budesonide in adult asthmatics. Chest 1998; 114: 1022-1027.

A127 AZIZ I, TAN KS, HALL IP, DEVLIN MM, LIPWORTH BJ. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. European Respiratory Journal 1998; 12: 580-584.

A128 AZIZ I, MCFARLANE LC, LIPWORTH BJ. Concomitant inhaled corticosteroid resensitises cardiac 2-adrenoceptors in the presence of long-acting 2-agonist therapy. European Journal of Clinical Pharmacology 1998; 54: 377-381.

A129 WILSON AM, BREWSTER HJA, LIPWORTH BJ. Dose response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. Journal of Allergy and Clinical Immunology 1998; 102: 751-756.

A130 WILSON AM, MCFARLANE LC, LIPWORTH BJ. Effects of intranasal corticosteroids on adrenal, bone and blood markers of systemic activity in allergic rhinitis. Journal of Allergy and Clinical Immunology 1998; 102: 598-604.

A131 WILSON AM, SIMS EJ, LIPWORTH BJ. Dose-response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clinical Endocrinology 1999; 50: 329-335.

A132 WILSON AM, SIMS EJ, STRUTHERS AD, LIPWORTH BJ. Inhaled corticosteroid therapy reduces the early morning peak in cortisol and aldosterone. Clinical Science 1998; 95: 513-517.

A133 ANHOI J, BISGARRD H, LIPWORTH BJ. Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. British Journal of Clinical Pharmacology 1999; 47: 333-336.

A134 WILSON AM, LIPWORTH BJ. 24 hour and fractionated profiles of adrenocortical activity in asthmatic patients receiving inhaled and intranasal corticosteroids. Thorax 1999; 54: 20-26.

A135 LIPWORTH BJ, HALL IP, TAN KS, AZIZ I, COUTIE WJ. Effects of genetic polymorphism on ex-vivo and in-vivo function of 2-adrenoceptors in asthmatic patients. Chest 1999; 115: 324-328.

A136 LIPWORTH BJ, AZIZ I. A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatics receiving regular salmeterol or formoterol. Journal of Allergy and Clinical Immunology 1999; 103: 88-92.

A137 LIPWORTH BJ, HALL IP, AZIZ I, TAN KS, WHEATLEY A. 2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short and long-acting 2-agonist therapy. Clinical Science 1999; 96: 253-259.

A138 AZIZ I, LIPWORTH BJ. A bolus of inhaled budesonide rapidly reverses airway subsensitivity and 2-adrenoceptor down-regulation after regular inhaled formoterol. Chest 1999; 115: 623-628.

A139 AZIZ I, LIPWORTH BJ. In-vivo effect of albuterol on methacholine contracted bronchi in the presence of salmeterol and formoterol. Journal of Allergy and Clinical Immunology 1999; 103: 816-822.

A140 AZIZ I, MCFARLANE LC, LIPWORTH BJ. Comparative trough effects of regular formoterol and salmeterol on lymphocyte 2-adrenoceptors and bronchodilatation. European Journal of Clinical Pharmacology 1999; 55: 431-436.

A141 DEMPSEY OJ, COUTIE WJR, WILSON AM, WILLIAMS P, LIPWORTH BJ. Evaluation of the buccal component of systemic absorption with inhaled fluticasone propionate. Thorax 1999; 54: 614-617.

A142 DEMPEY OJ, WILSON AM, COUTIE WJR, LIPWORTH BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionate metered dose inhaler. Chest 1999; 116: 935-940.

A143 WILSON AM, DEMPSEY OJ, COUTIE WJ, SIMS EJ, LIPWORTH BJ. Importance of drug-device interaction in determining systemic effects of inhaled corticosteroids. Lancet 1999; 353: 2128.

A144 WILSON AM, DEMPSEY OJ, SIMS EJ, COUTIE WJ, PATTERSON MC, LIPWORTH BJ. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clinical and Experimental Allergy 2000; 30: 833-838.

A145 WILSON AM, LIPWORTH BJ. Short-term dose-response relationships for relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatics. British Journal of Clinical Pharmacology 1999; 48: 579-585.

A146 LIPWORTH BJ, AZIZ I. Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration. Chest 2000; 117: 156-162.

A147 DEMPSEY OJ, WILSON AM, SIMS EJ, MISTRY C, LIPWORTH BJ. Additive bronchoprotective and bronchodilator effects of single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroid. Chest 2000; 117: 950-953.

A148 WILSON AM, SIMS EJ, ORR LC, LIPWORTH BJ. Differences in lung bioavailability between different propellants for fluticasone propionate. Lancet 1999; 354: 1357- 1358.

A149 WILSON AM, LIPWORTH BJ. Dose response evaluation of the therapeutic index for inhaled budesonide in patients with mild to moderate asthma American Journal of Medicine 2000; 108: 269-275.

A150 WILSON AM, DEMPSEY OJ, SIMS EJ, LIPWORTH BJ. Subjective and objective markers of treatment response in patients with seasonal allergic rhinitis. Annals of Allergy, Asthma and Immunology 2000; 85: 111-114.

A151 DAVIES R, CHET LEACH, LIPWORTH BJ, SHAW R. Asthma management with HFA-BDP (QVARTM). Hospital Medicine 1999; 60: 263-270.

A152 KEILLY DG, CARGILL RI, LIPWORTH BJ. Effects of acute oxygen therapy on left ventricular diastolic filling in hypoxaemic cor pulmonale. Appl Cardiopulm Pathophysiol 2000; 9: 27-31.

A153 LIPWORTH BJ, JACKSON CM. Pharmacokinetics of chloroflurocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate. British Journal of Clinical Pharmacology 1999; 48: 866-868.

A154 AZIZ I, WILSON AM, LIPWORTH BJ. Effects of once daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118: 1049-1058.

A155 LIPWORTH BJ, DEMPSEY OJ, AZIZ I. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 2-adrenoceptor polymorphism. Chest 2000; 118: 321-328.

A156 LIPWORTH BJ, DEMPSEY OJ, AZIZ I, WILSON AM. Effects of adding a leukotriene-antagonist or a long-acting 2-agonist in asthmatic patients with a glycine-16 beta-2-adrenoceptor genotype. American Journal of Medicine 2000; 109:114-121.

A157 WILSON AM, ORR L, SIMS EJ, LIPWORTH BJ. Effects of monotherapy with intranasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clinical and Experimental Allergy 2001; 31: 61-68.

A158 WILSON AM, DEMPSEY OJ, SIMS EJ, LIPWORTH BJ. Evaluation of salmeterol and montelukast as second-line therapy in asthmatic patients not controlled on inhaled corticosteroids. Chest 2001; 119: 1021-1026.

A159 FOWLER SJ, DEMPSEY OJ, SIMS EJ, LIPWORTH BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate: relationship to asthma severity and 2-receptor genotype. American Journal of Respiratory and Critical Care Medicine 2000; 162: 1318-1322.

A160 WILSON AM, ORR LC, SIMS EJ, DEMPSEY OJ, LIPWORTH BJ. Anti-asthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma. American Journal of Respiratory and Critical Care Medicine 2000; 162: 1297-1301.

A161 WILSON AM, SIMS EJ, ORR LC, COUTIE WJR, WHITE PS, GARDINER Q, LIPWORTH BJ. Effects of topical corticosteroid and combined mediator blockade in domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis and asthma. Annals of Allergy, Asthma and Immunology 2001; 87: 344-349.

A162 FOWLER SJ, WILSON AM, GRIFFITHS EA, LIPWORTH BJ. Comparative in vivo lung delivery of hydrofluroalkane salbutamol formulation via metered dose inhaler alone, plastic spacer or cardboard tube. Chest 2001; 119: 1018-1020.

A163 WILSON AM, DEMPSEY OJ, SIMS EJ, LIPWORTH BJ. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clinical and Experimental Allergy 2001; 31: 616-624.

A164 MCMAHON AD, LIPWORTH BJ, DAVEY PG, MORRIS AD, MACDONALD TM. Continuity of prescribing with inhaled corticosteroids and control of asthma. Pharmacoepidemiology and Drug Safety 2000; 9: 293-303.

A165 FOWLER SJ, LIPWORTH BJ. Pharmacokinetics and systemic 2-adrenoceptor mediated responses to inhaled salbutamol. British Journal of Clinical Pharmacology 2001; 51: 359-362.

A166 WILSON AM, WHITE PS, GARDINER Q, NASSIF R, LIPWORTH BJ. Effects of leukotriene receptor antagonist therapy in patients with chronic rhinosinusitis in real life rhinology clinic setting. Rhinology 2001, 38: 142-146.

A167 WILSON AM, FOWLER SJ, MARTIN SW, WHITE PS, GARDINER Q, LIPWORTH BJ. Evaluation of the importance of head and probe stabilization in acoustic rhinometry. Rhinology 2001, 39: 93-97.

A168 FOWLER SJ, ORR LC, WILSON AM, SIMS EJ, LIPWORTH BJ. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate. British Journal or Clinical Pharmacology 2001; 52: 93-95.

A169 DEMPSEY OJ, HUMPHREYS M, COUTIE WJR, LIPWORTH BJ. Relative lung delivery of luticasone propinate via large volume spacer or nebuliser in healthy volunteers. Eur J Clin Pharmacol 2001; 57: 637-41.

A170 LIPWORTH BJ, KOPPELMAN GH, WHEATLEY AP, LE JEUNE I, COUTIE W, MEURS H, KAUFFMAN HF, POSTMA DS, HALL IP. 2-adrenoceptor promotor polymorphisms: extended haplotypes and functional effects in peripheral blood mononuclear cells. Thorax 2002; 57: 61-66.

A171 DEMPSEY OJ, KENNEDY G, LIPWORTH BJ. Comparative efficacy and anti-inflammatory profile of once daily therapy with leukotriene antagonist or low dose inhaled corticosteroid in patients with mild persistent asthma. Journal of Allergy and Clinical Immunology 2002; 109: 68-74.

A172 DEMPSEY OJ, FOWLER J, WILSON AM, KENNEDY G, LIPWORTH BJ. Effects of adding either a leukotriene receptor antagonist or low dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002; 122: 151-159.

A173 FOWLER SJ, ORR LC, SIMS EJ, WILSON AM, CURRIE GP, MCFARLANE LC, LIPWORTH BJ. Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest 2002; 121: 618-623.

A174 SIMS EJ, WILSON AM, WHITE PW, GARDINER Q, LIPWORTH BJ. Short term repeatability and correlates of laboratory measures of nasal function in patients with seasonal allergic rhinitis. Rhinology 2002; 40: 66-68.

A175 CURRIE GP, FOWLER SJ, WILSON AM, SIMS EJ, ORR LC, LIPWORTH BJ. Airway and systemic effects of hyrdofluroalkane fluticasone and beclomethasone in patients with asthma. Thorax 2002; 57:865-868

A176 WILSON AM, ORR LC, COUTIE WJR, SIMS EJ, LIPWORTH BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domicliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exper All 2002; 32: 126-132.

A177 FOWLER SJ, HALL IP, WILSON AM, WHEATLEY AP, LIPWORTH BJ. 5-Lipoxygenase polymorphism and in-vivo response to leukotriene receptor antagonists. Eur J Clin Pharmacol 2002; 58: 187-190.

A178 WILSON AM, ORR LC, ROBB R, SIMS EJ, LIPWORTH BJ. Reproducibility of nasal function measurements with histamine and adenosine monophosphate nasal challenge testing in patients with allergic rhinitis. Allergology International 2003;52:155-160.

A179 FOWLER SJ, CURRIE GP, LIPWORTH BJ. Step-down therapy with low dose fluticasone/salmeterol combination or medium dose HFA-beclomethasone alone. J Allergy Clin Immunol 2002; 109: 929-935.

A180 WILSON AM, HAGGART K, SIMS EJ, LIPWORTH BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy 2002; 32:1504-1509

A181 CURRIE GP, LIPWORTH BJ. Bronchoprotective effects of leukotriene receptor antagonists in asthma. Chest 2002; 122:146-150.

A182 LIPWORTH BJ, LEE DKC, ANHOJ J, BISGAARD H. Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children. Br J Clin Pharmacol 2002; 54:544-547

A183 CURRIE GP, BATES CE, LEE DKC, JACKSON CM, LIPWORTH BJ. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003; 59: 11-15

A184 BLAYLOCK MG, LIPWORTH BJ, DEMPSTER OJ, DUNCAN CJA, LEE DKC, LAWRIE A, DOUGLAS JGD, WALSH GM. Eosinophils from patients with asthma express higher levels of the pan-leukocyte receptor CD45 and the isoform CD45RO. Clinical and Experimental Allergy 2003;33:936-941

A185 LEE DKC, ROBB F, SIMS EJ, CURRIE GP, MCFARLANE LC, LIPWORTH BJ. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. British Journal of Clinical Pharmacology 2003; 55:310-313

A186 LEE DKC, BATES CE, CURRIE GP, LIPWORTH BJ. Comparative in vivo bioactivity of modern H1-antihistamines on adenosine monophosphate challenge in atopic asthma. J Allergy Clin Immunol 2003;111:337-341.

A187 FOWLER SJ, LIPWORTH BJ. Relationship of skin prick reactivity to aeroallergens and hyperresponsiveness to methacholine and adenosine challenge. Allergy 2003; 58:46-52.

A188 ORR LC, FOWLER SJ, LIPWORTH BJ. Relationship between changes in quality of life and measures of lung function and bronchial hyperresponsiveness during high dose inhaled corticosteroid medicine in uncontrolled asthma. American Journal of Respiratory Medicine 2003;2:433-438

A189 CURRIE GP, HAGGART K, LEE DKC, WILSON AM, BRANNAN JD, ANDERSON SD, LIPWORTH BJ. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clinical and Experimental Allergy 2003; 33:783-788.

A190 WILSON AM, COCKBURN WJ, SIMS EJ, LIPWORTH BJ. The skin vasoconstrictor assay does not correlate significantly to airway or systemic responsiveness to inhaled budesonide in asthmatic patients. European Journal of Clinical Pharmacology 2003; 58:643-647.

A191 WILSON AM, SIMS EJ, ROBB F, COCKBURN WJ, LIPWORTH BJ. Peak inspiratory flow rate is more sensitive than acoustic rhinometry or rhinomanometry in detecting corticosteroid response with nasal histamine challenge. Rhinology 2003; 41:16-20.

A192 WILSON AM, SIMS EJ, ORR LC, ROBB F, LIPWORTH BJ. An evaluation of short term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge. British Journal of Clinical Pharmacology 2003; 55:354-359.

A193 FOWLER SJ, SYME-GRANT NJ, CASEY FA, LIPWORTH BJ. Evaluation of surrogate inflammatory markers for optimizing inhaled corticosteroid therapy in a real life clinical setting. Allergology International 2003; 52: 71-75.

A194 CURRIE GP, JACKSON CM, LEE DKC, LIPWORTH BJ. Determinants of airway hyperresponsiveness in mild asthma. Annals of Allergy, Asthma and Immunology 2003; 90: 560-563

A195 CURRIE GP, SYME-GRANT NJ, MCFARLANE LC, CAREY FA, LIPWORTH BJ. Effects of low dose fluticasone/salmeterol combination on surrogate inflammatory markers in moderate persistent asthma. Allergy 2003; 58: 602-607

A196 CURRIE GP, STENBACK S, LIPWORTH BJ. Effects of fluticasone versus fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. British Journal of Clinical Pharmacology 2003;56:11-17.

A197 SIMS EJ, JACKSON CM, LIPWORTH BJ. Add on therapy with montelukast or formoterol in patients with the glycine-16 B2 receptor genotype. British Journal of Clinical Pharmacology 2003;56:104-111.

A198 CURRIE GP, LEE DKC, DEMPSEY OJ, FOWLER SJ, CAVAN L, LIPWORTH BJ. A proof of concept study to evaluate positive benefits of montelukast in moderate persistent asthmatics. British Journal of Clinical Pharmacology 2003; 55:609-615

A199 CURRIE GP, LIMA JJ, SYLVESTER JE, LEE DKC, COCKBURN WJ, LIPWORTH BJ. Leukotriene C4 synthase polymorphisms and responsiveness to leukotriene antagonists in asthma. British Journal of Clinical Pharmacology 2003;56:422-426

A200 CURRIE GP, OGSTON SA, LIPWORTH BJ. Airway stabilizing effect of long acting B2-agonists as add on therapy to inhaled corticosteroids. Q J Med 2003; 96: 435-440

A201 CURRIE GP, HAGGART K, BRANNAN JD, LEE DKC, ANDERSON SD, LIPWORTH BJ. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58: 762-766

A202 CURRIE GP, JACKSON CM, LEE DKC, LIPWORTH BJ. Allergen sensitization and airway hyperresponsiveness to adenosine monophosphate in asthmatic patients. Clinical and Experimental Allergy 2003;33:1405-1408

A203 CURRIE GP, LEE DKC, HAGGART K, BATES CE, LIPWORTH BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid treated patients with asthma. Am J Respir Crit Care Med 2003; 167: 1232-1238.

A204 LEE DKC, HAGGART K, CURRIE GP, ANDERSON SD, LIPWORTH BJ. The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. Br J Clin Pharmacol 2003; 55: 639-642

A205 LEE DKC, CARSTAIRS IJ, HAGGART K, JACKSON CM, CURRIE GP, LIPWORTH BJ. Butterbur, a herbal remedy, attenuates adenosine monophosphate induced nasal responsiveness in seasonal allergic rhinitis. Clin Exp Allergy 2003; 33: 882-886.

A206 LEE DKC, JACKSON CM, CURRIE GP, COCKBURN WJ, LIPWORTH BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol 2003; 56:494-500

A207 LEE DKC, HAGGART K, JACKSON CM, LIPWORTH BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid treated atopic asthmatic patients. Chest 2004;125:1372-1377

A208 LEE DKC, CUTTIE GP, HALL IP, LIMA JJ, LIPWORTH BJ. The arginine-16 ß2 adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004;57:100-104

A209 LEE DKC, HAGGART K, ROBB FM LIPWORTH BJ. Butterbur, a herbal remedy, confers complimentary anti-inflammatory activity in asthmatic patients receiving inhaled corticosteroids. Clin Exper Allergy 2004;34:110-114

A210 LEE DKC, LIPWORTH BJ. The presence of emphysema does not affect the systemic bioactivity of inhaled fluticasone in severe chronic obstructive pulmonary disease. Br J Clin Pharmacol 2004; 57:388-392

A211 LEE DKC, HAGGART K, ROBB FM, LIPWORTH BJ. Montelukast protects against nasal; lysine-aspirin challenge in patients with aspirin-induced asthma. Eur Respir J 2004;24:226-230

A212 LEE DKC, JACKSON CM, SOUTAR TP, FUJIHARA S, LIPWORTH BJ. A placebo-controlled evaluation of butterbur and fexofenadine on objective and subjective outcomes in perennial allergic rhinitis. Clin Exp Allergy 2004; 34:650-653

A213 LEE DKC, JACKSON CM, BATES CE, LIPWORTH BJ. Cross-tolerance to salbutamol occurs independently of B2-adrenoceptor genotype-16 in patients receiveing regular formoterol or salmeterol. Thorax 2004;59:662-667

A214 LEE DKC, GARDINER MY, LIPWORTH BJ. Comparative effects of desloratadine, fexofenadine and levocetirizine on nasal adenosine monophosphate in patients with perennial allergic rhinitis. Clin Exp Allergy 2004;34:650-653

A215 LEE DKC, BATES CE, LIPWORTH BJ. Acute systemic effects of inhaled salbutamol in asthmatic subjects expressing common homozygousB2-adrenoceptor haplotypes at positions 16 and 27. Br J Clin Pharmacol 2004;57:68-75

A216 LEE DKC, HAGGART K, CURRIE GP, BATES CE, LIPWORTH BJ. Effects of hydrofluroalkane formulations of ciclesonide 400µg once daily versus fluticasone 250ug twice daily on methacholine hyperresponsiveness in mild to moderate persistent asthma. Br J Clin Pharmacol 2004;58:26-33

A217 LEE DKC, GRAY RD, WILSON AN, ROBB FM, SOUTAR PC, LIPWORTH BJ. Single and short term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br J Clin Pharmacol 2004;58:34-39

A218 LEE DKC, HAGGART K, LIPWORTH BJ. Reproducibility of response to nasal lysine-aspirin challenge in patients with aspirin-induced asthma. Ann Allergy Asthma Immunol 2004;93:185-188

A219 JACKSON CM, LEE DKC, LIPWORTH BJ. The effects of butterbur on the histamine and allergen cutaneuos response. Ann Allergy Asthma Immunol 2004;92:250-254

A220 SIMS EJ, LIPWORTH BJ. Concomitant occasional use of salbutamol influences bronchoprotective responsiveness afforded by formoterol in patients with the glycine-16 genotype. Eur J Clin Pharmacol 2004;59:791-795

A221 LEE DKC, JACKSON CM, SOUTAR PC, FARDON TC, LIPWORTH BJ. Effects of single or combined histamine H1 - receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol 2004;57:714-719

A222 FARDON TC, LEE DKC, HAGGART K, MCFARLANE LC, LIPWORTH BJ. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-966

A223 GRAY GD, HAGGART K, LEE DKC, CULL S, LIPWORTH BJ. Effects of butterbur treatment in intermittent allergic rhinitis: a placebo controlled evaluation. Annals of Allergy, Asthma and Immunology 2004;93:56-60

A224 LEE DKC, BATES CE, CURRIE GP, COWAN LM, McFARLANE LC, LIPWORTH BJ. Effects of high-dose inhaled fluticasone propionate on the hypothalamic-pituitary-adrenal axis in asthmatic patients with severely impaired lung function. Ann Allergy Asthma Immunol 2004;93:253-258.

A225 LIPWORTH BJ, SIMS EJ, TAYLOR K, COCKBURN WJ, FISHMAN R,. Dose-response to albuterol via a novel palm sized nebulizer-inhaler (Aerodose® Inhaler), conventional nebulizer (Pari LC Plus) and pMDI (Ventolin™ Evohaler™) in moderate severe asthmatics. Br J Clin Pharmacol 2005;59:5-13

A226 LIPWORTH BJ, SIMS EJ, DAS SK, BUCK H, PATERSON M,. Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol 2005;94:675-681

A227 FARDON TC, FARDON EJ, HODGE MR, LIPWORTH BJ. Comparative cutoff points for adenosine monophosphate and methacholine challenge testing. Ann Allergy Asthma Immunol 2004; 93: 365-372.

A228 LIPWORTH BJ, KALINER MA, LaFORCE CF, BAKER JW, KAISER HB, AMIN D, KUNDU S, WILLIAMS JE, ENGELSTAETTER R, BANERJI DD. Effect of ciclesonide and fluticasone on hypothalamic pituitary adrenal axis function in adults with mild to moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94:465-472

A229 LEE DKC, FARDON TC, BATES CE, HAGGART K, McFARLANE LC, LIPWORTH BJ. Airway and systemic effects of hydrofluoralkane formulations of high dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005;127:851-860

A230 LIPWORTH BJ, SIMS EJ, DAS SK, MORICE AH, O'CONNOR BJ. Bronchoprotection with formoterol via dry powder and metered does inhalers in asthmatics. Ann Allergy Asthma Immunol 2005;95:283-290

A231 FARDON TC, LEE DKC, HODGE MH, LIPWORTH BJ. Addition of fexofenadine to inhaled therapy to reduce inflammatory biomarkers in atopic asthma. Ann Allergy Asthma Immunol 2005;95:259-265

A232 FARDON TC, BURNS P, BARNES ML, LIPWORTH BJ. A comparison of two extra fine HFA-beclomethasone formulations on methacholine hyper-responsiveness. Ann Allergy Asthma Immunol 2006;96:422-430

A233 BARNES ML, BIALLOSTERSKI BT, GRAY RD, FARDON TC, LIPWORTH BJ. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology 2005;43:291-295

A234 FARDON TC, HODGE MH, LIPWORTH BJ. Evaluation of an abbreviated adenosine monophosphate bronchial challenge. Chest 2005;127:2222-2225A235

A235 KIELY DG, KENNEDY NS, PIRZADA O, BATCHELOR SA, STRUTHERS AD, LIPWORTH BJ. Elevated levels of natriuretic peptides in patients with pulmonary thromboembolism. Respiratory Medicine 2005;99:1286-1291

A236 WILSON AM, GRAY RD, HALL IP, LIPWORTH BJ. The effect of ß2-adrenoceptor haplotypes on bronchial hyperresponsiveness in patients with asthma. Allergy 2006:61;254-259

A237 BARNES ML, WARD JH, FARDON TC, LIPWORTH BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clinical and Experimental Allergy 2006:36;676-684

A238 BARNES ML, BIALLOSTERSKI BT, FUJIHARA S, GRAY RD, FARDON TC, LIPWORTH BJ. Effects of intranasal corticosteroid on nasal adenosine monophosphate challenge in persistent allergic rhnitis. Allergy 2006;61:1319-1325

A239 PALMER CAN, LIPWORTH BJ, LEE S, ISMAIL T, MacGREGOR DF, MUKHOPADHYAY S. The arginine-16 beta 2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006;61:940-944

A240 TAYAB ZR, FARDON TC, LEE DKC, HAGGART K, McFARLANE LC, LIPWORTH BJ, HOCKHAUS G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol 2007;64:698-705

A241 MENZIES D, NAIR A, WILLIAMSON PA, SCHEMBRI S, AL-KHAIRALLA MZH, BARNES M, FARDON TC, MCFARLANE L, MAGEE GJ, LIPWORTH BJ. Respiratory Symptoms, Pulmonary Function, and Markers of Inflammation Amongst Bar Workers Before and After a Legislative Ban on Smoking in Public Places. JAMA 2006;296:1742-1748

A242 BARNES ML, MENZIES D, FARDON TC, BURNS P, WILSON AM, LIPWORTH BJ. Combined mediator blockade or topical steroid for treating the unified allergic airway. Allergy 2007;62:73-80

A243 MENZIES D, NAIR A, MELDRUM K, FLEMING D, BARNES M, LIPWORTH BJ. Simvastatin does not exhibit therapeutic anti-inflammatory effects in asthma. J Allergy Clin Immunol 2007;119:328-335

A244 MENZIES D, NAIR A, LIPWORTH BJ. Portable exhaled nitric oxide measurement - Comparison with the "Gold Standard" technique. Chest 2007;131:410-414

A245 FARDON T, HAGGART K, LEE DKC, LIPWORTH BJ. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Resp. Med. 2007;101:1218-1228

A246 BARNES ML, MENZIES D, NAIR AR, HOPKINSON PJ, LIPWORTH BJ. A proof of concept study to assess the putative dose response to topical corticosteroid in persistent allergic rhinitis using adenosine monophosphate challenge. Clin Exp Allergy 2007;37:696-703

A247 MENZIES D, NAIR A, HOPKINSON P, McFARLANE L, LIPWORTH BJ. Differential anti-inflammatory effects of large and small particlae size inhaled corticosteroids in asthma. Allergy 2007;62:661-667

A248 MENZIES D, NAIR A, FARDON T, BARNES M, BURNS P, LIPWORTH B. An in-vivo and in-vitro comparison of inhaled steroid delivery via a novel vortex actuator and a conventional valved holding chamber. Ann Allergy Asthma Immunol 2007;98:471-479

A249 BARNES ML, LIPWORTH BJ. Removing nasal valve obstruction in peak nasal inspiratory flow measurement. Ann Allergy Asthma Immunol 2007;99:59-60